Accès gratuit
Med Sci (Paris)
Volume 20, Numéro 2, Février 2004
Page(s) 169 - 174
Section M/S revues
Publié en ligne 15 février 2004
  1. Capron L. Étiologie de l’athérosclérose. Rev Prat 1999; 49 : 2 100–3.
  2. Nieto FJ. Infections and atherosclerosis : new clues from an old hypothesis ? Am J Epidemiol 1998; 148 : 937–48.
  3. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med 1978; 148 : 335–40.
  4. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2 : 983–5.
  5. Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis : critical assessment of diagnostic methods and relevance to treatment strategies. Clin Microb Rev 2002; 15 : 1–20.
  6. Mendall M, Goggin P, Levy J, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71 : 437–9.
  7. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96 : 404–7.
  8. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q wave coronary syndromes : ROXIS pilot study. Lancet 1997; 350 : 404–7.
  9. Epstein SE, Zhu JH, Burnett MS, Zhou YF, Vercellotti G, Hajjar D. Infection and atherosclerosis : potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol 2000; 20 : 1 417–20.
  10. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart disease risk. JAMA 2000; 284 : 1 406–10.
  11. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105 : 15–21.
  12. Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. Br Med J 2000; 321 : 208–12.
  13. Smieja M, Chong S, Natarajan M, et al. Circulating nucleic acids of Chlamydia pneumoniae and cytomegalovirus in patients undergoing coronary angiography. J Clin Microbiol 2001; 39 : 596–600.
  14. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease : is there a link ? Lancet 1997; 350 : 430–6.
  15. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke 2001; 32 : 385–90.
  16. Farsak B, Yildirir A, Akyon Y, et al. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol 2000; 38 : 4408–11.
  17. Capron L. Chlamydia in coronary plaques : Hidden culprit or harmless hobo ? Nat Med 1996; 2 : 856–7.
  18. Fabricant CG. Atherosclerosis : the consequence of infection with a herpesvirus. Adv Vet Sci Comp Med 1985; 30 : 39–66.
  19. Capron L. How to design vaccination trials to prevent atherosclerosis. Am Heart J 1999; 138 : S558–9.
  20. Morré SA, Stooker W, Lagrand WK, van den Brule AJC, Niessen HWM. Microorganisms in the aetiology of atherosclerosis. J Clin Pathol 2000; 53 : 647–54.
  21. Gaydos CA. Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J Infect Dis 2000; 181 : S473–8.
  22. Stone AFM, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes : South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106 : 1 219–23.
  23. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999; 20 : 89–92.
  24. Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndromes. Circulation 2002; 105 : 1 555–60.
  25. Cercek B. Azithromycin in acute coronary syndrome investigators. The effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndrome. Program and abstracts of the American College of Cardiology, 51st Annual Meeting, March 17-20, 2002. Atlanta, Georgia : American College of Cardiology, 2002 (abstract 405-3).
  26. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation 2000; 102 : 1755–60.
  27. Neumann FJ, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3) : a randomised, double-blind, placebo-controlled trial. Lancet 2001; 357 : 2 085–9.
  28. Dunne M, O’Connor C, Pfeffer M, Muhlestein B, Gupta S, Yao L. Weekly intervention with zithromax for atherosclerosis and its related disorders (the WIZARD Study). Program and abstracts of the American College of Cardiology, 51st Annual Meeting, March 17-20, 2002. Atlanta, Georgia : American College of Cardiology, 2002 (abstract 405-4).
  29. Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered form atherosclerotic coronary arteries. Antimicrob Agents Chemother 1998; 42 : 2762–4.
  30. Schneider C, Diedrich H, Riedel KD, et al. In vivo uptake of azithromycin in human coronary plaque. Am J Cardiol 2000; 86 : 789–91.
  31. Beatty W, Morrison R, Byrne G. Persistent Chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58 : 686–99.
  32. Gieffers J, Füllgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103 : 351–6.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.